NeuroSense Therapeutics Ltd. (NRSNW) Stock Price & Analysis

NeuroSense Therapeutics Ltd. (NRSNW) Healthcare & Pipeline Overview

NeuroSense Therapeutics Ltd., an Israeli clinical-stage biotechnology firm, pioneers treatments for neurodegenerative diseases, primarily focusing on ALS with its lead candidate PrimeC. The company operates in a competitive biotech landscape, emphasizing novel oral formulations to address unmet medical needs in neurodegenerative disorders.

What Is the Investment Thesis for NRSNW?

NeuroSense Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently tied to the clinical progress of PrimeC, its lead candidate for ALS, and the advancement of its preclinical assets, StabiliC and CogniC. Successful clinical trials for PrimeC could serve as a significant value driver, addressing a critical unmet need in ALS treatment. However, the company's financial viability depends on securing additional funding, given its current market capitalization of $0.00B and negative P/E ratio of -2.40. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's ability to secure partnerships or funding to mitigate risks associated with biotechnology investments. Beta is 1.61.

Based on FMP financials and quantitative analysis

NRSNW Key Highlights

NeuroSense Therapeutics focuses on developing treatments for neurodegenerative diseases, including ALS, Parkinson's, and Alzheimer's.

• Lead product candidate, PrimeC, is a novel oral formulation for ALS treatment.
• Preclinical pipeline includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease.
• The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
• The company has a market capitalization of $0.00B and a P/E ratio of -2.40.

Who Are NRSNW's Competitors?

NRSNW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NRSNW's Key Strengths?

Focus on neurodegenerative diseases with high unmet needs.

• Novel oral formulation for ALS treatment (PrimeC).
• Preclinical pipeline targeting Parkinson's and Alzheimer's diseases.
• Experienced management team in biotechnology development.

What Are NRSNW's Weaknesses?

Limited financial resources and market capitalization.

• Dependence on successful clinical trials for PrimeC.
• Early stage of development for preclinical assets.
• Competition from larger, more established biotechnology companies.

What Are the Key Risks for NRSNW?

Failure to secure additional funding to support ongoing clinical trials and research activities.

• Unfavorable clinical trial results for PrimeC or other product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from other companies developing treatments for neurodegenerative diseases.

What Threats Does NRSNW Face?

• Clinical trial failures or delays.
• Regulatory hurdles and approval timelines.
• Competition from existing and emerging therapies.
• Funding constraints and market volatility.

What Are NRSNW's Competitive Advantages?

• Proprietary drug formulations and delivery technologies.
• Patent protection for key product candidates.
• Clinical data demonstrating efficacy and safety.
• Expertise in neurodegenerative disease research and development.

What Does NRSNW Do?

NeuroSense Therapeutics Ltd., established in 2017 and headquartered in Herzliya, Israel, is a clinical-stage biotechnology company dedicated to the discovery and development of treatments for debilitating neurodegenerative diseases. The company's primary focus is on addressing conditions with significant unmet medical needs, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. NeuroSense's lead product candidate, PrimeC, is a novel oral formulation designed for the treatment of ALS. This drug aims to improve patient outcomes by targeting key mechanisms involved in the progression of the disease. In addition to PrimeC, NeuroSense has a preclinical pipeline that includes StabiliC for Parkinson's disease and CogniC for Alzheimer's disease, both of which are in the early stages of development. The company's strategy involves leveraging innovative scientific approaches and collaborations to advance its pipeline and bring new therapies to patients suffering from these devastating conditions. With a team of 17 employees, NeuroSense is committed to making a meaningful impact in the field of neurodegenerative disease treatment.

What Products and Services Does NRSNW Offer?

• Develop treatments for neurodegenerative diseases.
• Focus on amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease.
• Develop novel oral formulations for drug delivery.
• Conduct preclinical and clinical trials to evaluate drug efficacy and safety.
• Seek regulatory approvals for new therapies.
• Explore strategic partnerships for research and development.

How Does NRSNW Make Money?

• Develop and patent novel drug formulations.
• Conduct clinical trials to demonstrate efficacy and safety.
• Seek regulatory approval from health authorities.
• Commercialize approved therapies through partnerships or direct sales.

What Industry Does NRSNW Operate In?

NeuroSense Therapeutics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on neurodegenerative diseases, a sector with a growing prevalence due to aging populations. Key competitors include companies like ACXP, ADIL, ADXN, APRE, and BCLI, all vying to develop innovative treatments for similar conditions. The market for neurodegenerative disease treatments is projected to grow substantially, driven by increasing diagnosis rates and the demand for more effective therapies.

Who Are NRSNW's Key Customers?

• Patients suffering from neurodegenerative diseases.
• Healthcare providers who treat these patients.
• Pharmaceutical companies seeking to license or acquire new therapies.
• Research institutions involved in neurodegenerative disease research.

Company Profile

NeuroSense Therapeutics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Herzliya, IL. The company is led by CEO Alon Ben-Noon. NRSNW has traded publicly since 2021.

Key Financial Metrics

Its free cash flow yield is -52.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.31 means current liabilities exceed short-term assets, a liquidity point worth watching.

NeuroSense Therapeutics Ltd. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 5.4% below estimates on average.

Wall Street analysts project NeuroSense Therapeutics Ltd. revenue of about $714K for fiscal 2026, with EPS near $-6.62. The estimate reflects 3 contributing analysts.

2 transactions · 2 purchases, 0 sales, 0 other transactions · 2 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jun 16, 2026. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

NRSNW Financials

NRSNW Latest News

NRSNW Analyst Consensus

NRSNW MoonshotScore

Common Questions About NRSNW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources